249 related articles for article (PubMed ID: 31661345)
1. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
Matsushima T; Akira S; Yoneyama K; Takeshita T
Gynecol Endocrinol; 2020 Jun; 36(6):521-524. PubMed ID: 31661345
[TBL] [Abstract][Full Text] [Related]
2. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
3. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis.
Takaesu Y; Nishi H; Kojima J; Sasaki T; Nagamitsu Y; Kato R; Isaka K
J Obstet Gynaecol Res; 2016 Sep; 42(9):1152-8. PubMed ID: 27225336
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
5. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
Kitawaki J; Kusuki I; Yamanaka K; Suganuma I
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):212-6. PubMed ID: 21474232
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
7. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
Ota K; Takahashi T; Shiraishi S; Mizunuma H
J Obstet Gynaecol Res; 2018 Sep; 44(9):1787-1792. PubMed ID: 29998482
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
Fawzy M; Mesbah Y
Arch Gynecol Obstet; 2015 Dec; 292(6):1267-71. PubMed ID: 25990480
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis].
Zhang HY; Zhu S; Xu W; Wang AQ; Wang XL
Zhonghua Fu Chan Ke Za Zhi; 2022 Nov; 57(11):856-863. PubMed ID: 36456483
[No Abstract] [Full Text] [Related]
10. Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study.
Chan IS; Hsu TF; Shih YC; Chang YH; Wang PH; Chen YJ
Int J Gynaecol Obstet; 2023 Jun; 161(3):751-759. PubMed ID: 36527263
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
Hirata T; Izumi G; Takamura M; Saito A; Nakazawa A; Harada M; Hirota Y; Koga K; Fujii T; Osuga Y
Gynecol Endocrinol; 2014 Oct; 30(10):726-9. PubMed ID: 24905725
[TBL] [Abstract][Full Text] [Related]
12. Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas.
Ozaki R; Kumakiri J; Jinushi M; Ikuma S; Murakami K; Kawasaki Y; Kitade M
Arch Gynecol Obstet; 2020 Oct; 302(4):969-976. PubMed ID: 32661756
[TBL] [Abstract][Full Text] [Related]
13. Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery.
Seo JW; Lee DY; Kim SE; Yoon BK; Choi D
Eur J Obstet Gynecol Reprod Biol; 2019 May; 236():53-57. PubMed ID: 30884336
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
15. High-intensity focused ultrasound (HIFU) combined with gonadotropin-releasing hormone analogs (GnRHa) and levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis: a case series with long-term follow up.
Haiyan S; Lin W; Shuhua H; Wang W
Int J Hyperthermia; 2019; 36(1):1179-1185. PubMed ID: 31793356
[No Abstract] [Full Text] [Related]
16. Long-term dienogest administration in patients with symptomatic adenomyosis.
Neriishi K; Hirata T; Fukuda S; Izumi G; Nakazawa A; Yamamoto N; Harada M; Hirota Y; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
J Obstet Gynaecol Res; 2018 Aug; 44(8):1439-1444. PubMed ID: 29845696
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Hassanin AI; Youssef AA; Yousef AM; Ali MK
Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
[TBL] [Abstract][Full Text] [Related]
18. Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
Xue J; Li L; Li F; Li N; Li T; Li C
J Reprod Immunol; 2020 Feb; 137():103079. PubMed ID: 31927399
[TBL] [Abstract][Full Text] [Related]
19. Gonadotrophin-releasing hormone agonist combined with high-intensity focused ultrasound ablation for adenomyosis: a clinical study.
Guo Y; Duan H; Cheng J; Zhang Y
BJOG; 2017 Aug; 124 Suppl 3():7-11. PubMed ID: 28856862
[TBL] [Abstract][Full Text] [Related]
20. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
